REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot117710.21518/1561-5936-2019-12-36-43Original ArticleBig Data Analytics of EHRs: pathogenic relations of cancer with Ischaemic Heart Disease and Diabetes MellitusKolesnichenkoO. Yu.oykolesnichenko@list.ruKolesnichenkoYu. Yu.uzgraph@gmail.comPulitV. V.valeriy.pulit@sparm.comMartynovA. V.martynov@sparm.comSotnikA. Yu.A_SOTNIK@protek.ruKhaykinaI. A.iakhaykina@gmail.comMarochkinaE. B.doc-lena45@mail.ruMinushkinaL. O.minushkina@mail.ruPimenovaK. V.kseniyksp@gmail.comBugakovaA. S.aleksandra_bugakova@rambler.ruVasilyevaE. Yu.lena.vasilyeva777@yandex.ruKomarovR. N.komarovroman@rambler.ruGolovanovA. V.doc.moncha1@gmail.comI.M. Sechenov First Moscow State Medical UniversityUzgraphSP.ARMZAO (CJSC) Firm CV PROTEKCentral State Medical Academy at the Department of Presidential AffairsAlmazov National Medical Research Centre1212201912364318032022Copyright © 2019,2019The incidences of cancer in patients with ischaemic heart disease and diabetes mellitus (types 1 and 2) were analyzed according to the electronic health records (medical information system qMS). For several years, a predominance of prostate cancer and colorectal cancer in almost 10 thousand patients with ischaemic heart disease were revealed; in patients with diabetes mellitus type 1 lung cancer was prevailed; and in patients with diabetes mellitus type 2 colorectal cancer and lung cancer were prevailed. Prostate cancer and ischaemic heart disease are associated with a general imbalance within estrogen receptors ERα, ERβ, gpER, which occurs in old age with reproductive function fading. Hyperglycemia in diabetes mellitus causes a blocking of the parathyroid hormone-related protein signaling pathway, which creates a favorable environment for carcinogenesis in the lungs. Hyperinsulinemia, as a result of insulin resistance in diabetes mellitus and in metabolic syndrome accompanying ischaemic heart disease, triggers signaling pathways, including mTOR, which contribute to the carcinogenesis in the large intestine epithelium. Three different patient samples showed the different pictures of tumor localization, and for each of the identified predominant cancer localization common signaling pathways with a concomitant metabolic disease can be distinguished.Ischaemic Heart Diseaseatherosclerosisestrogen receptorsDiabetes Mellitusinsulinprostate cancercolorectal cancermedical information system qMSBig DataИБСатеросклерозэстрогеновые рецепторыСДинсулинрак предстательной железыколоректальный ракМИС qMSБольшие данные[Masoudkabir F., Sarrafzadegan N., Gotay C., Ignaszewski A., Krahn A.D., Davis M.K., Franco C., Mani A. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;(263):343–351. doi: 10.1016/j.atherosclerosis.2017.06.001.][Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. The New England Journal of Medicine. 1999;340(23):1801–1811. doi: 10.1056/NEJM199906103402306.][Kassi E., Spilioti E., Nasiri-Ansari N., Adamopoulos C., Moutsatsou P., Papapanagiotou A., Siasos G., Tousoulis D., Papavassiliou A.G. Vascular Inflammation and Atherosclerosis: The Role of Estrogen Receptors. Current Medicinal Chemistry. 2015;22(22):2651–2665. doi: 10.2174/0929867322666150608093607.][Nelson A.W., Tilley W.D., Neal D.E., Carroll J.S. Estrogen receptor beta in prostate cancer: friend or foe? Endocrine-Related Cancer. 2014;21(4):T219–T234. doi: 10.1530/ERC-13-0508.][Yasar P., Ayaz G., User S.D., Güpür G., Muyan M. Molecular mechanism of estrogen-estrogen receptor signaling. Reproductive Medicine and Biology. 2017;16(1):4–20. doi: 10.1002/rmb2.12006.][Deroo B.J., Korach K.S. Estrogen receptors and human disease. Journal of Clinical Investigation. 2006;116(3):561–70. doi: 10.1172/JCI27987.][Lee H.R., Kim T.H., Choi K.C. Functions and physiological roles of two types of estrogen receptors, ERα and ERβ, identified by estrogen receptor knockout mouse. Laboratory Animal Research. 2012;28(2):71–76. doi: 10.5625/lar.2012.28.2.71.][Korach K.S. et al. Physiological and Pathological Roles of Estrogen Receptor. In: Zhang X. (eds) Estrogen Receptor and Breast Cancer. Cancer Drug Discovery and Development. Humana Press, Cham; 2019:15–47. doi: 10.1007/978-3-319-99350-8_2.][Vermeulen A., Kaufman J.M., Goemaere S., Van Pottelberg I. Estradiol in elderly men. The Aging Male. 2002;(5):98–102. doi: 10.1080/tam.5.2.98.102.][Dickson R.B., Clark C.R. Estrogen Receptors in the Male. Archives of andrology. 1981;(7):205–217. doi: 10.3109/01485018108999309.][Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis. 2000;21(3):427–433. doi: 10.1093/carcin/21.3.427.][Barton M., Filardo E.J., Lolait S.J., Thomas P., Maggiolini M., Prossnitz E.R. Twenty years of the G protein-coupled estrogen receptor GPER: historical and personal perspectives. The Journal of Steroid Biochemistry and Molecular Biology. 2018;(176):4–15. doi: 10.1016/j.jsbmb.2017.03.021.][Meyer M.R., Fredette N.C., Daniel C., Sharma G., Amann K., Arterburn J.B., Barton M., Prossnitz E.R. Obligatory role for GPER in cardiovascular aging and disease. Science Signaling. 2016;9(452):ra105. doi: 10.1126/scisignal.aag0240.][Barton M., Prossnitz E.R. Emerging Roles of GPER in Diabetes and Atherosclerosis. Trends in Endocrinology & Metabolism. 2015;26(4):185–192. doi: 10.1016/j.tem.2015.02.003.][Hadjimarkou M.M., Vasudevan N. GPER1/GPR30 in the brain: Crosstalk with classical estrogen receptors and implications for behavior. The Journal of Steroid Biochemistry and Molecular Biology. 2018;(176):57–64. doi: 10.1016/j.jsbmb.2017.04.012.][Figueira M.I., Cardoso H.J., Socorro S. The Role of GPER Signalingin Carcinogenesis: A Focus on Prostate Cancer. Chapter 5. In: Fayyaz S., Farooqi A.A. (eds.). Recent Trends in Cancer Biology: Spotlight on Signaling Cascades and microRNAs. Springer International Publishing AG; 2018:59–118. doi: 10.1007/978-3-319-71553-7.][Bäck M., Yurdagul A.Jr., Tabas I., Öörni K., Kovanen P.T. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nature Reviews Cardiology. 2019;16(7):389-406. doi: 10.1038/s41569-019-0169-2.][Steyers C.M.3rd, Miller F.J.Jr. Endothelial Dysfunction in Chronic Inflammatory Diseases. International Journal of Molecular Sciences. 2014;15(7):11324–11349. doi: 10.3390/ijms150711324.][Gistera, A., Hansson, G.K. The immunology of atherosclerosis. Nature Reviews Nephrology. 2017;13(6):368–380. doi: 10.1038/nrneph.2017.51.][Горбунова Е.Н., Давыдова Д.А., Крупин В.Н. Хроническое воспаление и фиброз как факторы риска простатических интраэпителиальных неоплазий и рака предстательной железы. Современные технологии в медицине. 2011;(1):79–83. Режим доступа: http://www.stm-journal.ru/ru/numbers/2011/1/704.][Yang J., Nishihara R., Zhang X., Ogino S., Qian Z.R. Energy sensing pathways: bridging type 2 diabetes and colorectal cancer? Journal of Diabetic Complications. 2017;31(7):1228–1236. doi: 10.1016/j.jdiacomp.2017.04.012.][Giouleme O., Diamantidis M.D., Katsaros M.G. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World Journal of Gastroenterology. 2011;17(4):444–448. doi: 10.3748/wjg.v17.i4.444.]